Combating the Novel Coronavirus (COVID-19): Week of Feb. 21

MHA Covid-19 update

MHA Covid-19 updateThe current surge of hospitalizations due to COVID-19 has continued its downward trend. The seven-day average of hospitalizations in the U.S. as of Feb. 22 was 53,987, down from 146,534 Jan. 20. Michigan hospitalizations for confirmed and suspected cases of COVID-19 included 1,282 adults and 45 children as of Feb. 25, down from the Jan. 20 totals of 4,554 adults and 130 children.

The MHA continues to keep members apprised of pandemic-related developments affecting hospitals through email updates and the MHA Coronavirus webpage. Important updates are outlined below.

Outpatient Therapeutics Alert Issued

The Michigan Department of Health and Human Services (MDHHS) issued Feb. 24 a Health Alert Network alert to providers regarding changes to COVID-19 outpatient therapeutics. Here are the two primary changes as defined by the MDHHS:

  • The Priority Eligibility Criteria limitations have been removed due to increasing COVID-19 outpatient medication accessibility and decreasing disease activity.
  • The revised standard prescribing forms for Paxlovid and molnupiravir are attached.

The alert explains that until recently, options for outpatient therapies for patients with mild to moderate COVID-19 have often been in limited supply, necessitating prioritizing eligibility to those at higher risk. As current COVID-19 activity declines and with increasing medication supply, there is no longer a need for limiting eligibility beyond the requirements established by the Food and Drug Administration. In the event of future COVID-19 surges and/or reductions in supply, prioritization may need to be reestablished.

Facilities administering medications by an intravenous route may be limited in their capacity to provide therapy and may need to establish criteria to assure higher risk patients are treated first. Oral medications are available at all Meijer pharmacies and selected other non-Meijer pharmacies. Sites administering monoclonal antibody therapy can be found at www.michigan.gov/covidtherapy.

The fillable/printable standardized prescribing order forms have also been revised, removing eligibility criteria. Electronic prescriptions are preferred and should be revised to reflect these changes.

Additional information on the COVID-19 pandemic is available to members on the MHA Community Site and the MHA COVID-19 webpage. Questions on COVID-19 and infectious disease response strategies may be directed to the MDHHS Community Health Emergency Coordination Center (CHECC).

Combating the Novel Coronavirus (COVID-19): Week of Oct. 18

MHA Covid-19 update

MHA Covid-19 updateThe MHA continues to keep members apprised of pandemic-related developments affecting hospitals through email updates and the MHA Coronavirus webpage. Important updates are outlined below.

CDC, FDA Approve Moderna and J&J Boosters, Mix and Match Strategy

The director of the Centers for Disease Control and Prevention (CDC) Oct. 21 formally endorsed the use of COVID-19 booster shots from Moderna and Johnson & Johnson (J&J) for some adults. This comes on the heels of the Oct. 20 approval from the Food and Drug Administration (FDA).

The actions authorize a Moderna booster for people 65 and older and for all adults who either have underlying conditions or work in settings where they’re more likely to be exposed to the virus. Those people may obtain the Moderna booster, which is half the size of each dose used for initial vaccination, six months after completing the primary vaccine series.

The agencies also recommended all adults who received the J&J single-shot vaccine get a booster at least two months post-immunization. In addition, the agencies agreed that people who are eligible can choose any type of booster, regardless of whether they initially received the Pfizer, Moderna or J&J version. This decision may help individuals who have a higher risk of side effects with a particular brand of vaccine.

Healthcare providers are encouraged to continue monitoring for email updates from the Michigan Department of Health and Human Services (MDHHS) and Health Alert Network for details regarding booster dose administration. The MDHHS has also posted updated fact sheets for the vaccines on its website for vaccinating providers.

The MHA continues to promote both factual and anecdotal messaging about the safety and effectiveness of COVID-19 vaccines. The association is also using messaging on flu vaccines, urging people to get vaccinated and practice smart preventive measures to help avoid “twindemic” status and add to the stress on the healthcare system.

Members with vaccine questions may contact Ruthanne Sudderth at the MHA.

MHA Urges Medicaid to Cover Merck COVID-19 Treatment Pill

The MHA submitted comments Oct. 18 to state Medical Services Administration officials, urging them to add molnupiravir, Merck’s new COVID-19 treatment pill, to the Medicaid Health Plan Common Formulary if it is approved by the FDA. The medication has been shown to effectively treat COVID-19 and reduce death and hospitalization. Importantly, it comes in pill form that the patient takes at home, unlike current antibody treatments that must be administered by health and hospital professionals, using time and resources that are currently scarce. The association will keep members apprised of the FDA’s review of the treatment and any action by the state to add it to the Common Formulary.

Additional information on the COVID-19 pandemic is available to members on the MHA Community Site and the MHA COVID-19 webpage. Questions on COVID-19 and infectious disease response strategies may be directed to the MDHHS Community Health Emergency Coordination Center (CHECC).